AVTX-002

Evidence outlook · lead readout

NCT05288504 · Non-Eosinophilic Asthma

The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.

NCT05288504: Participants were randomized and double-blinded to AVTX-002 or placebo, with 45 participants analyzed in each group. The primary clinical endpoint was the occurrence of asthma-related events, but the reported counts were close and no p-value or confidence interval was provided, so the result cannot be classified as clearly positive or negative.